US biotech Sirnaomics has won Food and Drug Administration ( FDA ) approval to test its STP705 treatment , an RNA inference ( RNAi ) candidate , for bile duct cancer . It was given orphan status for CCA and a fibrotic disease affecting the bile duct, primary sclerosing cholangitis (PSC), last year. It has already been trialled for scar - reduction treatment . Sirnaomics said STP705 downregulated cancer - causing fibroblast activity in and around a tumour which restricted its development . Sirnaomics said it had been working on RNAi treatments for more than a decade . It raised $ 25 m from Chinese investors in June to fund its development . Two clinical trials are planned for later this year in the US , Europe and China where it has a partnership with Guangzhou Xiangxue Pharma .
US biotech Sirnaomics has won Food and Drug Administration ( FDA ) approval to test its STP705 treatment , an RNA inference ( RNAi ) candidate , for bile duct cancer . It has already been trialled for scar - reduction treatment . Sirnaomics said STP705 downregulated cancer - causing fibroblast activity in and around a tumour which restricted its development . Sirnaomics said it had been working on RNAi treatments for more than a decade . It raised $ 25 m from Chinese investors in June to fund its development . Two clinical trials are planned for later this year in the US , Europe and China where it has a partnership with Guangzhou Xiangxue Pharma .